03 Aug, 2017 RNAi Roundtable: Patisiran, in Development for the Treatment of Hereditary ATTR Amyloidosis
On August 3, 2017, we hosted an online RNAi Roundtable to review the progress with patisiran, an RNAi therapeutic in development for the treatment of hereditary ATTR amyloidosis.
- Jared Gollob, M.D., Vice President, Clinical Research
- Moderator: Eric Green, Vice President, General Manager, TTR Program
- Guest Speaker: Michael Polydefkis, M.D., Director, Cutaneous Nerve Lab, Professor of Neurology, Johns Hopkins University School of Medicine